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Whenever adrenal cancer (ACC) is completely removed we should face the 
dilemma to treat by means of adjuvant therapy or not. In our opinion, adjuvant 
mitotane is the preferable approach in most cases because the majority of 
patients following radical removal of an ACC have an elevated risk of recurrence. 
A better understanding of factors that influence prognosis and response to 
treatment will help in stratifying patients according to their probability of 
benefiting from adjuvant mitotane, with the aim of sparing unnecessary toxicity 
to patients who are likely unresponsive. However, until significant 
advancements take place, we have to deal with uncertainty using our best 
clinical judgement and personal experience in the clinical decision process. In 
the present paper, we present the current evidence on adjuvant mitotane 
treatment and describe the management strategies of patients with ACC after 
complete surgical resection. We acknowledge the limit that most 
recommendations are based on personal experience rather than solid evidence. 
 
 Adjuvant mitotane treatment: what is the evidence? 
Adrenal cancer (ACC) is a rare tumor characterized by a poor prognosis since 5-
year survival rate after diagnosis is less than 40 % [1–3]. The main factor 
influencing prognosis is the possibility of a radical surgery; however, most of the 
tumors which undergo a complete, margin-free resection will recur, often with 
distant metastases [4–8]. This observation has prompted to consider systemic 
therapy following the removal of ACC; mitotane, a parent compound of the 
insecticide DDT, has been the drug most frequently employed in an adjuvant 
setting [1–3, 5–8]. 
It is known from many years that administration of mitotane was able to destroy 
the adrenal glands in animal models [9] and to inhibit different enzymatic steps 
of adrenal steroidogenesis [10]. It is generally thought that mitotane cytotoxicity 
is mediated through binding of the reactive acyl-chloride to mitochondrial 
proteins and subsequent oxidative damage through generation of free radicals 
[10, 11]. It has also been demonstrated that mitotane is able to sensitize H295R 
and SW-13 ACC cells to ionizing radiations by attenuating DNA repair and 
interfering with cell proliferation [12]. These findings suggest that mitotane, in 
addition to the assumed binding to proteins and phospholipids, may interact 
also with DNA. The activity of mitotane depends on metabolic transformation of 
the drug in the mitochondria catalyzed by a P-450 enzyme, giving adrenal 
selectivity [13]. 
Mitotane has a narrow therapeutic index and the potential to cause significant 
toxicity [3, 6, 7]; thus, it is not an ideal drug to treat patients free of disease. This 
concept coupled with a limited evidence of efficacy in the literature published 
since recently [5–8, 13–17] made adjunctive treatment with mitotane 
progressively less appealing. As a matter of fact, no recommendation in favor or 
against adjuvant treatment was formulated at a consensus conference on ACC 
held at Ann Arbor in 2003 [18]. 
In 2007, we published a retrospective analysis involving a large cohort of 
patients with ACC, followed at different institutions in Italy and Germany, which 
challenged this view [19]. In that study, adjuvant mitotane was given to 47 
Italian patients after radical surgery, and recurrence-free survival in these 
patients was compared with that of two independent groups of 55 Italian and 75 
German patients whose surgical procedures were not followed by mitotane 
treatment. Recurrence-free survival (the primary outcome of the study) was 
significantly prolonged in the mitotane group, while the patients who were left 
untreated after radical resection of ACC had a significantly higher recurrence 
rate. Multivariate analysis confirmed that mitotane treatment gave a significant 
advantage for recurrence-free survival and also overall survival after adjusting 
for an imbalance of prognostic factors among the different groups [19]. An 
important finding of the study was that a favorable effect was achieved with low 
doses (1–5 g per day), a possible explanation for the acceptable adverse event 
rate [13]. Conversely, severe and disabling toxicity was observed in the previous 
series employing high doses of mitotane [6]. 
Following publication of our study, Bertherat et al. [20] reported that in a cohort 
of 166 patients, mitotane use following complete tumor removal was not 
associated with any improvement in disease-free survival. Since mitotane was 
given to only half of the patients referred to the Authors’ institution a selection 
bias may be anticipated, implying that patients with unfavorable prognostic 
factors were selected for adjuvant mitotane treatment. This is a major difference 
with our study, in which the choice to recommend mitotane was made 
according to a predefined center policy irrespective of patient or tumor 
characteristics [19]. The predefined treatment assignment and the inclusion of 
well-matched control groups were considered to be the major advantages of our 
study as compared with other studies that had less clear treatment assignments 
and often used historical controls or no controls at all [13]. However, the 
conclusions of our study, given its retrospective nature, have been heavily 
criticized [21]. Arguments against adjuvant mitotane are based on the 
methodological flaws of the available evidence, inherent complexity of mitotane 
treatment, and lack of factors predicting response to treatment and the toxicity 
profile of the drug [10]. 
More recently, 3 studies addressed the issue of adjuvant mitotane and provided 
evidence of its efficacy. Although the study from the M.D. Anderson Cancer 
Center claimed that a state-of-the-art surgical approach may provide a similar 
survival to surgery plus adjuvant mitotane, the lack of adjuvant mitotane 
treatment was a factor predicting a higher risk of recurrence [23]. Moreover, a 
small cohort of patients treated with adjuvant mitotane had a better disease-
free survival notwithstanding that they were treated by less experienced 
surgeons outside the institution; however, adjuvant mitotane did not affect 
overall survival [22]. Fassnacht and colleagues [23] found that survival was 
improved in patients with stage II ACC who were managed by a specialized 
center early after surgery compared to patients who were referred at a later 
stage, usually after tumor recurrence. Adjuvant mitotane was more frequently 
used in the first group and treatment was associated with a survival advantage 
[23]. Wangberg and colleagues [24] reviewing their experience with ACC, 
showed that an aggressive surgical approach associated with the use of adjuvant 
mitotane was associated with a satisfactory disease-specific survival. The benefit 
of mitotane was evident for patients with high-stage ACC and circulating drug 
levels >14 mg/l [24]. 
Controversy on adjuvant mitotane is deemed to continue unless results of 
prospective, controlled studies become available. We have launched the first 
randomized trial in an adjuvant setting for ACC, the ADIUVO study, 
(http://www.adiuvo-trial.org) under the endorsement of the European Network 
for the Study of Adrenal Tumours (ENS@T). The study’s aim is to assess the 
efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in 
patients with ACC at low-intermediate risk of recurrence. Results of ADIUVO may 
not be expected before 2017. 
 
 Management of adjuvant mitotane treatment 
Nowadays, mitotane monitoring is readily available across Europe, where it is 
provided as a free service by the company distributing mitotane (info@lysodren-
europe.com). Mitotane monitoring is a key for an appropriate management of 
adjuvant treatment giving the possibility to guide dose adjustments and target 
mitotane concentrations that have been associated with a therapeutic effect. 
Indeed, plasma mitotane levels >14 mg/l have been found to predict tumor 
response and improve survival in patients with advanced ACC [15, 16, 25]. 
Preliminary results of our group demonstrated that the concept of a relationship 
between plasma concentrations of mitotane and its efficacy is applicable also to 
disease-free patients who are treated by means of adjuvant therapy [26]. 
At San Luigi Hospital, we recommend adjuvant mitotane in the patients 
perceived to be at high risk of recurrence, while the remainders are encouraged 
to enter the ADIUVO trial. Although our capability of predicting future risk of 
ACC recurrence after radical surgery and death is limited, it is generally agreed 
that stage III—IV ACC, margin-positive resection, and an elevated mitotic index 
are all factors portending an unfavorable prognosis [27]. Stage IV ACC may be 
susceptible to complete removal of the primary and metastatic tumor sites, but 
this condition may be assimilated to a margin-positive resection. Even if solid 
evidence is lacking, it is usually thought that these patients with stage IV tumors 
require postoperative medical treatment [28]. An elevated mitotic index is 
increasingly recognized as a negative prognostic factor and studies showed that 
cutoff values of 10 % for Ki-67 or 9 mitoses per high-power microscopic field 
were able to categorize patients at high risk of recurrence [28, 29]. 
In our practice, we start adjunctive mitotane treatment as soon as possible after 
surgery, in any case within 3 months. Although a high-dose regimen is able to 
provide therapeutic plasma concentrations of mitotane within 1 month in about 
one third of the patients [30], we are more cautious with dose escalation 
(Table 1). A high-dose regimen requires an intensive follow-up and may be more 
frequently associated with side effects, while our schedule is better tolerated 
and has less impact on the quality of life. Anyway, we are currently using higher 
doses than in the past [31] acknowledging the importance of shortening time 
necessary to reach target mitotane concentrations. 
The most common unwanted effects are gastrointestinal manifestations that 
appear early, independently on mitotane levels. They can be managed with 
temporary dose reduction, or delay of dose increments, and supportive therapy. 
Elevated γ-glutamyltransferase levels are also frequently observed but are not 
actually troublesome unless values are exceedingly elevated. Clinically significant 
liver toxicity is characterized by a marked increase in transaminases and 
bilirubin, but is infrequently observed in the absence of predisposing conditions 
[3, 28, 30–32]. Central neurologic toxicity (cerebellar symptoms, disturbed 
cognitive performance) is more closely associated with elevated mitotane 
concentrations (>20 mg/l) but subtler symptoms, such as memory impairment or 
attention deficit, may be observed in some patients even when they are exposed 
to lower drug concentrations [15, 16, 32]. A great individual variability in the 
susceptibility to mitotane-related unwanted effects is apparent for causes that 
are still unknown. 
Because of the adrenolytic effect of mitotane, all patients should receive 
glucocorticoid replacement to prevent adrenal insufficiency. Steroid doses are 
typically higher than in Addison’s disease, due to an enhanced metabolic 
clearance rate of glucocorticoids induced by mitotane [34]. An inadequate 
treatment of adrenal insufficiency increases mitotane-related toxicity, 
particularly gastrointestinal side-effects, and reduces tolerance [3, 28, 33]. 
Mineralocorticoid supplementation is not mandatory in all patients because the 
zona glomerulosa is partly spared by the toxic effect of mitotane [3, 28, 33]. 
Moreover, mitotane affects thyroid and gonadal function in a complex way by 
mechanisms that are still to be completely elucidated. Mitotane administration 
is associated with low FT4 levels without a compensatory rise in TSH, an effect 
that becomes apparent early in the course of treatment. This prompts thyroxin 
replacement, even if the benefit of this measure is difficult to appreciate [28, 32, 
33]. In women, gonadal function is usually preserved and most female patients 
have regular cycles unless PRL levels are significantly increased [28, 32, 33] due 
to a weak estrogen-like action of mitotane [35]. Conversely, in men mitotane 
treatment causes sexual dysfunction as a late but common unwanted effect, due 
to inhibition of testosterone secretion. Sex steroid replacement may become 
necessary to treat erectile dysfunction in some patients but may worsen 
gynecomastia (Table 2) [28, 32, 33]. 
A general measure to deal with mitotane toxicity is a step down to the 
previously tolerated dose, or temporary drug withdrawal in the event of severe 
manifestations. However, well-informed and motivated patients are able to cope 
with side effects and maintain compliance to treatment. To accomplish this task, 
it is important to establish a close patient–physician relationship to induce and 
maintain adherence to treatment. Patients seek advice frequently, also because 
their local physicians are unfamiliar with mitotane use and its attendant 
complications, and it is necessary to give a timely counseling to keep patients on 
treatment. 
The optimal duration of therapy remains undefined. Since most ACC recurrences 
after complete resection occur within 2 years from primary surgery, in our 
practice we consider such a period as a landmark [28, 33]. However, we are 
eager to prolong treatment if well tolerated in patients at elevated risk. 
 
 Conclusion 
Whenever ACC is completely removed we should face the dilemma to treat by 
means of adjuvant therapy or not. In our opinion, adjuvant mitotane is the 
preferable approach in most cases, because the majority of patients referred to 
our institution following adrenalectomy have an elevated risk of recurrent 
disease. 
A better understanding of factors that influence prognosis and response to 
treatment [36, 37] will help in stratifying patients according to their probability 
of benefiting from adjuvant mitotane, with the aim of sparing unnecessary 
toxicity to patients who are likely unresponsive. However, until significant 
advancements take place, we have to deal with uncertainty using our best 
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 Tables: 
Table 1 Practical guidelines to manage patients on adjuvant mitotane treatment: 
 
✓ Start with 1 g daily and increase mitotane dose every 4–7 days up to 8–10 g daily, or the 
maximum tolerated dose. Give mitotane in split doses with meals or snacks 
✓ Accommodate mitotane schedule to patient’s tolerance 
✓ Aim at serum mitotane concentrations of 14–20 mg/l 
✓ Check mitotane levels after 4 weeks from treatment start to adjust dosage 
✓ Thereafter, check mitotane levels every 4–8 weeks until reaching target levels (14–
20 mg/l). Then, mitotane dose can be reduced and levels checked less frequently 
✓ In case of slight unwanted effects, continue mitotane and treat symptoms (e.g., nausea, 
diarrhea) accordingly 
✓ In case of moderate side effects, step down to the previously tolerated dose and use 
symptomatic therapy 
✓ In case of severe side effects, discontinue mitotane and institute specific treatment. 
Duration of treatment stop depends on clinics and mitotane levels. After interruption, restart 
with a lower dose 
✓ At steady state, clinical assessment, biochemical, and hormonal evaluation, and monitoring 
of mitotane levels every 3–4 months, or in case of significant side-effects. Adjust mitotane 
dose according to circulating levels and tolerability 
 




Table 2 Hormone replacement during adjuvant mitotane treatment: 
 
✓ Start glucocorticoid replacement at initiation of mitotane treatment 
✓ Replace glucocorticoid at higher doses than usual (50 mg hydrocortisone–75 mg cortisone 
acetate, or even larger daily doses, may be needed in the long-term) 
✓ Glucocorticoid replacement is monitored best with careful clinical assessment and 
measurement of electrolytes, since assessment of serum cortisol is confounded by the 
mitotane-induced increase in CBG. Assessment of UFC is confounded by enhanced steroid 
metabolism and current steroid supplementation 
✓ Look for clinical and biochemical signs of mineralocorticoid deficiency in the long term; give 
fludrocortisone if needed 
✓ Look for hypogonadism, particularly in long-term treated men, heralded by low free 
testosterone levels. Total testosterone may be normal due to the mitotane-induced increase 
in SHBG 
✓ Replace testosterone in the event of erectile dysfunction or impotence. Gynecomastia may 
be simply due to the estrogenic effect of mitotane 
✓ Low T4 levels associated with normal TSH are frequently observed. Replace thyroxin when 
T4 levels are markedly low and symptoms of hypothyroidism (somnolence, decreased 
attention) are apparent 
 
Recommendations based on personal experience and Ref. [29] CBG cortisol-binding globulin, 
SHBG sex-hormone binding globulin 
